Citi initiated coverage of Veradermics (MANE) with a Buy rating and $85 price target The firm believes the company’s VDPHL01 is positioned to become the first FDA-approved oral minoxidil for pattern hair loss. The drug will enter a $30B market with a major unmet need, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MANE:
- Veradermics initiated with a Buy at Jefferies
- Veradermics initiated with an Overweight at Cantor Fitzgerald
- Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO
- Veradermics completes enrollment in Phase 3 trial of VDPHL01
- Veradermics Completes IPO and Adopts New Governance Structure